Genetically modified immune cells take on eight cancer types in early trial
NCT ID NCT04044859
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy drugs. Up to 120 adults with cancers like lung, ovarian, or melanoma are enrolled to check safety and initial signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADP-A2M4CD8 T-cells (genetically modified immune cells) alone or with nivolumab or pembrolizumab
- What this could lead to
- If successful, this could point toward a new treatment option for several hard-to-treat cancers that express MAGE-A4.
- What could go wrong
- This is an early Phase 1 trial with only 120 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the cell therapy and immune checkpoint inhibitors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Universitaria de Navarra
Pío, Pamplona, 31008, Spain
-
Duke University Medical Center, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico de Valencia
Ibanez, Valencia, 46010, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Avenida de Cordoba S/n, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro CIOCC
Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Name of Institution: Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Washington University - School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- What raises endometrial cancer risk in black women? a study digs in
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?